Skip to main content
Anupam Rasayan India Limited logo

Anupam Rasayan India Limited — Investor Relations & Filings

Ticker · ANURAS ISIN · INE930P01018 LEI · 3358004GQZY8E2J1SV40 BSE.NS Manufacturing
Open in API
Filings indexed 553 across all filing types
Latest filing 2026-05-23 Regulatory Filings
Country IN India
Listing BSE.NS ANURAS

About Anupam Rasayan India Limited

https://www.anupamrasayan.com/

Anupam Rasayan India Limited specializes in the custom synthesis and manufacturing (CSM) of specialty chemicals. The company operates primarily in two business verticals: life science-related specialty chemicals and other specialty chemicals. Its product portfolio includes high-value intermediates for agrochemicals, personal care, and pharmaceuticals, as well as specialty pigments, dyes, and polymer additives. The firm is recognized for its expertise in complex multi-step synthesis and diverse chemistries, such as fluorination, hydrogenation, and nitration. Anupam Rasayan serves a global clientele, including several multinational corporations across Europe, Japan, and the United States. With a strong focus on research and development, it maintains advanced manufacturing facilities and provides end-to-end solutions from process development to commercial-scale production, ensuring high quality and sustainability standards.

Recent filings

Filing Released Lang Actions
Resignation of Director/KMP/SMP
Regulatory Filings
2026-05-23 English
Investor Presentation regarding Bliss GVS Pharma Limited Acquisition.
Investor Presentation Classification · 92% confidence The document is an official notification to stock exchanges (BSE and NSE) under SEBI LODR Regulation 30, enclosing an ‘Investor Presentation’ regarding the Bliss GVS Pharma acquisition. The content consists of slide decks detailing company overview, transaction details, financials, strategy, and market position. This matches the definition of an Investor Presentation (IP).
2026-05-23 English
Investor Presentation
Investor Presentation Classification · 92% confidence The document is a notification under SEBI LODR Regulation 30 enclosing a slide deck titled “Investor Presentation – Acquisition”. It contains detailed presentation slides on the Bliss GVS Pharma acquisition including overviews, financial charts, transaction structure and sources of funds. This matches the definition of an Investor Presentation (IP), not an earnings release or proxy material.
2026-05-23 English
Investor Presentation in respect of Audited Financial Results for the quarter and financial year ended March 31, 2026.
Investor Presentation Classification · 95% confidence The document is titled “Investor Presentation – Q4 & FY26” and begins with a letter to stock exchanges under Regulation 30 of the SEBI LODR enclosing an investor presentation. The body consists entirely of slide content (financial highlights, MD’s message, P&L, balance sheet, business overview, strategic milestones, etc.). It is not a formal annual report, earnings release, or regulatory certification but a detailed presentation for investors. Therefore, it should be classified as an Investor Presentation (IP).
2026-05-23 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled “Investor Presentation– Q4 & FY26,” references Regulation 30 of SEBI, and contains slide-style financial highlights, business overviews, MD’s message, and detailed P&L, balance sheet, and cash flow tables formatted as a presentation. It is not merely a notice pointing to an external report, nor a regulatory certification or transcript. This matches the definition of an Investor Presentation.
2026-05-23 English
Press Release
M&A Activity Classification · 85% confidence The document is a formal stock exchange filing under SEBI LODR Reg 30, enclosing a press release announcing that Anupam Rasayan India Ltd. has entered into a definitive agreement to acquire 43.3–48.2% equity stake in Bliss GVS Pharma and launch an open offer to public shareholders. This is clearly an announcement related to a takeover/open‐offer transaction, which falls under M&A Activity filings.
2026-05-23 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.